北京贝尔生物工程股份有限公司（下称"贝尔生物"）的上市之路再次按下了"暂停键"，这家老牌体外诊 断企业曾在五年内多次转换赛道、冲击IPO，至今未果。 2025年9月29日，北京证券交易信息显示，贝尔生物的IPO审核状态变更为"中止"。这是这家成立于1995 年的老牌体外诊断企业自2020年以来第三次冲击资本市场，再次遇到波折。 多次闯关IPO 贝尔生物的IPO之路可谓一波三折。 2020年7月，贝尔生物首次申请在深交所创业板上市，但2021年2月就撤回了申请。经历短暂调整后，公 司在2021年10月转战上交所主板。 然而这一尝试同样并未如愿，直到2025年4月，贝尔生物改道北交所。6月30日，贝尔生物北交所IPO获 受理。但仅仅三个月后，公司的上市进程再度停止。 此次IPO中止的直接原因是"财务报告到期补充审计事项"。据北交所规则，公司需更新财务资料，而贝 尔生物主动选择了中止审核。 本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 据招股书，贝尔生物计划将募集资金分别投入以下两个项目： 体外诊断试剂及仪器生产基地建设项目，拟投入募集资金4.42亿元，用于扩大现有产品的生产能力，建 设新的 ...

10月10日，利德曼盘中上涨2.01%，截至10:38，报7.61元/股，成交4721.55万元，换手率1.15%，总市值 41.40亿元。 资金流向方面，主力资金净流入293.52万元，特大单买入142.01万元，占比3.01%，卖出0.00元，占比 0.00%；大单买入848.17万元，占比17.96%，卖出696.67万元，占比14.76%。 利德曼今年以来股价涨55.31%，近5个交易日跌0.13%，近20日跌3.79%，近60日涨41.19%。 利德曼所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、辅助生殖、体 外诊断、冷链物流、小盘等。 截至9月19日，利德曼股东户数3.35万，较上期减少4.99%；人均流通股16192股，较上期增加5.26%。 2025年1月-6月，利德曼实现营业收入1.60亿元，同比减少14.80%；归母净利润-424.52万元，同比减少 800.43%。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 机构持仓方面，截止2025年6月30日，利德曼十大流通股东中，金元顺安元启灵活配置混合（004685） 位居第八 ...

10月9日，针对"圣湘董事长戴立忠创立核聚变公司"的消息，圣湘生物方面向中国证券报记者回应称， 戴立忠是鸿鹄聚变(上海)能源科技有限公司(简称"鸿鹄聚变")实控人，目前该项目只涉及戴立忠个人投 资，戴立忠不参与鸿鹄聚变的日常运营工作。 仅涉及个人投资 圣湘生物也在投资者互动平台上做了回应，聚变能源作为有望彻底解决全球能源危机和环境问题的终极 能源形式，已成为全球能源科技竞争的战略高地，上海市已明确将核聚变列为重点发展的未来产业。鸿 鹄聚变成立于2023年，系圣湘生物实控人、董事长戴立忠投资创立的企业，也是国内专注于高温超导仿 星器路线的商业聚变企业。 已关注和研究多年 圣湘生物是以自主创新基因技术为核心，集体外诊断试剂、仪器、第三方医学检验服务及生物制药为一 体的诊疗一体化方案提供商。公司2025年半年报显示，公司上半年共实现营收8.69亿元，同比增长 21.15%；实现归母净利润1.63亿元，同比增长3.84%；实现扣非净利润1.36亿元，同比增长12.19%。 圣湘生物2024年年报显示，戴立忠系北京大学学士，美国普林斯顿大学硕士、博士，麻省理工学院博士 后，现任圣湘生物法定代表人、董事长、总经理。先后当 ...

核聚变赛道有多大吸引力？ 据证券时报，针对"圣湘董事长戴立忠创立核聚变公司"的消息，圣湘生物方面向记者回应称，戴立忠是鸿鹄聚变（上海）能源科技有限公司投资人与实控 人，目前该项目只涉及戴立忠个人投资，戴立忠不参与鸿鹄聚变的的日常运营工作。 据公司官网介绍，圣湘生物科技股份有限公司是以自主创新基因技术为核心，集体外诊断试剂、仪器、第三方医学检验服务及生物制药为一体的诊疗一体 化方案提供商。公司在科创板上市（股票代码：，并跻身中国医药工业百强及全球医疗器械企业TOP100榜单。 公司以长沙、上海为双战略支点，辐射全国、布局全球。在北京、成都、广州、武汉等全国主要城市和英国、法国、美国、印尼、菲律宾、泰国等全球重 要区域设立了分子公司或分支机构，构建起全球化运营网络。 来源：wind 公开资料显示，戴立忠，1968年7月出生，中国国籍，无境外永久居留权。北京大学学士，美国普林斯顿大学硕士、博士，麻省理工学院博士后。先后当 选第十三届、十四届全国人大代表，第三届中国慈善联合会副会长；是国家高层次人才，国务院特殊津贴专家，中国侨界十杰，长沙市A类人才（国际顶 尖人才）；荣获国家科技进步二等奖、全国创新争先奖、中国专利银 ...

万泰生物所属申万行业为：医药生物-生物制品-疫苗。所属概念板块包括：体外诊断、抗原检测、猴痘 概念、幽门螺杆概念、疫苗等。 截至6月30日，万泰生物股东户数3.84万，较上期增加24.00%；人均流通股32958股，较上期减少 19.36%。2025年1月-6月，万泰生物实现营业收入8.44亿元，同比减少38.25%；归母净利润-1.44亿元， 同比减少155.30%。 分红方面，万泰生物A股上市后累计派现15.41亿元。近三年，累计派现13.11亿元。 机构持仓方面，截止2025年6月30日，万泰生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2275.44万股，相比上期增加515.08万股。华泰柏瑞沪深300ETF（510300）位居第九大流 通股东，持股672.44万股，相比上期增加71.58万股。易方达沪深300医药ETF（512010）位居第十大流 通股东，持股622.30万股，相比上期减少50.92万股。招商国证生物医药指数A（161726）退出十大流通 股东之列。 10月9日，万泰生物盘中上涨2.05%，截至11:01，报57.71元/股，成交1.59亿元，换手率0.22%，总 ...

Group 1 - The core viewpoint of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. has seen a stock price increase of 5.34%, reaching 162.43 CNY per share, with a total market capitalization of 10.311 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has Haobio as a significant investment, holding 56,100 shares, which constitutes 5.74% of the fund's net value [2] - The fund, Shenwan Hongyuan Medical Pioneer Stock A, has a current scale of 120 million CNY and has experienced a loss of 2.93% this year, ranking 4172 out of 4220 in its category [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 75 days, with the best and worst fund returns during his tenure being -30.26% and -31.14%, respectively [2]

证券日报网讯 9月26日晚间，美康生物发布公告称，公司于近日取得了由浙江省药品监督管理局颁发的 《中华人民共和国医疗器械注册证（体外诊断试剂）》。 （文章来源：证券日报） ...

Company Overview - Jiangsu Shuoshi Biological Technology Co., Ltd. was established on April 12, 2010, and listed on December 5, 2019. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [2] - The main business revenue composition includes: testing reagents 85.89%, purchased instruments and materials 7.19%, testing instruments 3.84%, testing services 2.24%, and others 0.84% [2] - As of September 19, the number of shareholders is 8,000, a decrease of 4.82% from the previous period, with an average of 10,483 circulating shares per person, an increase of 5.06% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 176 million yuan, a year-on-year decrease of 1.05%, and a net profit attributable to the parent company of 3.99 million yuan, a year-on-year decrease of 86.35% [2] - The company has distributed a total of 1.37 billion yuan in dividends since its A-share listing, with 285 million yuan distributed over the past three years [3] Stock Performance - As of September 26, the stock price of Shuoshi Biological fell by 2.08% to 64.02 yuan per share, with a total market value of 5.369 billion yuan [1] - Year-to-date, the stock price has increased by 56.13%, but it has decreased by 5.28% in the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 19.7845 million yuan on February 17 [1] Institutional Holdings - As of June 30, 2025, the third-largest circulating shareholder is Huaxia Industry Prosperity Mixed A (003567), holding 2.2546 million shares, an increase of 1.0079 million shares from the previous period [3]

Core Viewpoint - Lepu Medical experienced a stock price decline of 2.08% on September 26, with a trading price of 17.42 yuan per share and a total market capitalization of 32.76 billion yuan [1] Financial Performance - Lepu Medical's revenue for the first half of 2025 was 3.369 billion yuan, a year-on-year decrease of 0.43%, while the net profit attributable to shareholders was 691 million yuan, down 0.91% year-on-year [2] - The company has cumulatively distributed 4.957 billion yuan in dividends since its A-share listing, with 2.058 billion yuan distributed in the last three years [3] Stock Market Activity - The stock price of Lepu Medical has increased by 57.68% year-to-date, but it has seen a decline of 4.96% in the last five trading days and 7.59% over the past 20 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 29.5585 million yuan on June 4 [1] Shareholder Structure - As of June 30, 2025, Lepu Medical had 100,100 shareholders, an increase of 6.18% from the previous period, with an average of 16,152 circulating shares per shareholder, down 5.82% [2] - Major shareholders include Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with changes in their holdings noted [3]

Group 1 - The stock of Jiangsu Haobio Pharmaceutical Co., Ltd. fell by 5.08% on September 23, trading at 141.21 CNY per share, with a total transaction volume of 1.21 billion CNY and a turnover rate of 1.31%, resulting in a total market capitalization of 8.964 billion CNY [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with its main revenue sources being reagent sales (89.46%), other sales (5.86%), instrument sales (3.84%), and rental sales (0.85%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Penghua Fund has a significant position in Haobio, specifically the Penghua Anyue One-Year Holding Period Mixed A Fund (011071), which held 7,962 shares, accounting for 0.58% of the fund's net value, ranking as the tenth largest holding [2] - The Penghua Anyue One-Year Holding Period Mixed A Fund was established on February 9, 2021, with a current scale of 183 million CNY, yielding a return of 10.79% year-to-date, ranking 5,659 out of 8,172 in its category, and a one-year return of 12.47%, ranking 6,599 out of 7,995 [2] - The fund manager, Wang Shiqian, has been in position for 7 years and 182 days, managing total assets of 22.415 billion CNY, with the best fund return during his tenure being 112.28% and the worst being -6.06% [2]